Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
It is the first hospital in the country to achieve the significant milestone of completing over 2600 robotic surgeries for treating patients with prostate, kidney and urinary bladder cancer
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
The launch is yet another first of its kind innovation in India
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
Subscribe To Our Newsletter & Stay Updated
